Overview

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study. The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of ME1111 after repeated daily topical application of ME1111 in a maximal use setting in adults with distal subungual onychomycosis of the toenails.
Phase:
Phase 1
Details
Lead Sponsor:
Meiji Seika Pharma Co., Ltd.
Treatments:
Pharmaceutical Solutions